Atyr Pharma Inc (NASDAQ: ATYR) kicked off on Tuesday, up 2.16% from the previous trading day, before settling in for the closing price of $3.24. Over the past 52 weeks, ATYR has traded in a range of $1.42-$4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 429.49% over the past five years. While this was happening, its average annual earnings per share was recorded 20.82%. With a float of $86.14 million, this company’s outstanding shares have now reached $89.00 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -390.64%, operating margin of -28899.57%, and the pretax margin is -27243.4%.
Atyr Pharma Inc (ATYR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 64.15%. The most recent insider transaction that took place on Mar 17 ’25, was worth 15,000. In this transaction Director of this company bought 3,750 shares at a rate of $4.00, taking the stock ownership to the 9,750 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 1,254 for $3.78, making the entire transaction worth $4,740. This insider now owns 31,763 shares in total.
Atyr Pharma Inc (ATYR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 20.82% per share during the next fiscal year.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Take a look at Atyr Pharma Inc’s (ATYR) current performance indicators. Last quarter, stock had a quick ratio of 7.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Atyr Pharma Inc (NASDAQ: ATYR) saw its 5-day average volume 1.16 million, a negative change from its year-to-date volume of 1.3 million. As of the previous 9 days, the stock’s Stochastic %D was 35.52%. Additionally, its Average True Range was 0.27.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 42.80%, which indicates a significant increase from 40.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.75% in the past 14 days, which was lower than the 84.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.28, while its 200-day Moving Average is $2.97. Nevertheless, the first resistance level for the watch stands at $3.41 in the near term. At $3.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.68. If the price goes on to break the first support level at $3.14, it is likely to go to the next support level at $2.97. The third support level lies at $2.87 if the price breaches the second support level.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
The company with the Market Capitalisation of 294.60 million has total of 89,004K Shares Outstanding. Its annual sales at the moment are 240 K in contrast with the sum of -64,020 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -14,880 K.
